Latest Gynecologic Oncology Group Stories
A clinical trial has sifted out the most effective single-drug chemotherapy regimen for quick-growing but highly curable cancers that arise from the placentas of pregnant women.
An analysis conducted by Ohio State University cancer researchers has found that adding the targeted therapy bevacizumab to the treatment of patients with advanced ovarian cancer is not cost effective.
Selected abstract points to efficacy of treatment guidelines and need for improved practices CHICAGO, Feb.
A small proportion of adult cancer patients participate in clinical trials in part due to a low level of physician referrals.
Research by the American Academy of Family Physicians demonstrates that vulvar cancer occurs most frequently in women age 65 to 75 years of age.
CHICAGO, Jan. 24, 2011 /PRNewswire-USNewswire/ -- The Society of Gynecologic Oncologists (SGO) will host its 42nd Annual Meeting on Women's Cancer March 6-9, 2011, at the Hilton Bonnet Creek & Waldorf Astoria Orlando in Orlando, Florida.
HUNTSVILLE, Ala., Dec. 13, 2010 /PRNewswire/ -- EGEN, Inc. today announced that the first Phase II clinical trial utilizing EGEN-001 for the treatment of recurrent ovarian cancer is now open for enrollment.
CALGARY, Dec. 1 /PRNewswire/ - Oncolytics Biotech Inc. ("Oncolytics") (TSX:ONC, NASDAQ:ONCY) announced today the start of enrollment in a randomized Phase II ovarian cancer study.
New wordoncancer.org Website Launched To Spread Awareness about Gynecologic Cancers by Womenâ€™s Oncology Research & Dialogue (WORD) Women's Oncology Research & Dialogue has lanched a new website to inform women about ovarian, uterine, cervical and all gynecologic cancers at wordoncancer.org. Indianapolis, IN (PRWEB) November 9, 2010 On November 9, 2010 Womenâ€™s Oncology Research & Dialogue launched their new website at http://www.wordoncancer.org. WORD was founded...
TORONTO, Sept. 2 /PRNewswire-FirstCall/ - Oncolytics Biotech Inc.